Tricyclic sulfones as RORγ modulators
US-10273259-B2 · Apr 30, 2019 · US
Tricyclic sulfones as RORγ modulators
US10711020B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10711020-B2 |
| Application number | US-201916295378-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 7, 2019 |
| Priority date | May 7, 2015 |
| Publication date | Jul 14, 2020 |
| Grant date | Jul 14, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There are described RORγ modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating inflammatory bowel disease, Crohn's disease and ulcerative colitis in a subject, the method comprising administering to the subject a therapeutically-effective amount of a compound of the formula or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
Assignees
Inventors
Classifications
- C07D215/36Primary
Sulfur atoms (C07D215/24 takes precedence) · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
containing three or more hetero rings · CPC title
without antiinflammatory effect · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10711020B2 cover?
- There are described RORγ modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modu…
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D215/36. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).